Belantamabe mafodotin-blmf recebe aprovação acelerada do fda para pacientes com mieloma múltiplo recidivado ou refratário

Referências

1. Lonial, S et al., Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol, 2020, 21(2): 207-221.

2. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma